Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elobixibat (GOOFICE) to prevent hepatotoxicity after Kasai surgery in biliary atresia
jRCTs041240187Recruiting
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of elobixibat in biliary atresia. Primary endpoint: Serum bile acid concentration. Started Feb 2025; status: recruiting.
02
Drugs
elobixibat
03
Conditions
biliary atresia
Beyond the preview
Go deeper on jRCTs041240187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240187.